Giuseppe Cianchini

Summary

Affiliation: Istituto Dermopatico dell'Immacolata
Country: Italy

Publications

  1. doi request reprint Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up
    Giuseppe Cianchini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Rome, Italy
    J Am Acad Dermatol 67:617-22. 2012
  2. ncbi request reprint Pemphigus foliaceus induced by radiotherapy and responsive to dapsone
    Giuseppe Cianchini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    J Dermatolog Treat 17:244-6. 2006
  3. ncbi request reprint Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature
    Giuseppe Cianchini
    Division of Dermatology, Istituto Dermopatico dell Immacolata, IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy
    Arch Dermatol 143:1033-8. 2007
  4. ncbi request reprint Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid
    Alessandra Frezzolini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata, IDI, IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy
    Eur J Dermatol 12:27-31. 2002
  5. doi request reprint Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools
    Andrea Paradisi
    Health Services Research Unit, Istituto Dermopatico dell Immacolata Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
    J Am Acad Dermatol 60:261-9. 2009
  6. pmc Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface
    Giovanni Di Zenzo
    Molecular and Cell Biology Laboratory, Istituto Dermopatico dell Immacolata, IDI IRCCS, Rome, Italy
    J Clin Invest 122:3781-90. 2012
  7. ncbi request reprint Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial
    Leon F Mentink
    Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Arch Dermatol 142:570-6. 2006
  8. pmc Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
    Dedee F Murrell
    Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
    J Am Acad Dermatol 58:1043-6. 2008

Collaborators

Detail Information

Publications8

  1. doi request reprint Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up
    Giuseppe Cianchini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Rome, Italy
    J Am Acad Dermatol 67:617-22. 2012
    ..However, differences in inclusion criteria, treatment protocols, and follow-up make it difficult to derive uniform conclusions...
  2. ncbi request reprint Pemphigus foliaceus induced by radiotherapy and responsive to dapsone
    Giuseppe Cianchini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    J Dermatolog Treat 17:244-6. 2006
    ..The eruption started at the portal of irradiation and only subsequently spread to other cutaneous areas. Mucosal membranes were not affected. Skin lesions were completely responsive to dapsone therapy...
  3. ncbi request reprint Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature
    Giuseppe Cianchini
    Division of Dermatology, Istituto Dermopatico dell Immacolata, IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy
    Arch Dermatol 143:1033-8. 2007
    ..We report 10 cases of pemphigus vulgaris and 2 cases of pemphigus foliaceous treated with rituximab--to our knowledge the largest series of patients so far--and review the existing literature on the topic...
  4. ncbi request reprint Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid
    Alessandra Frezzolini
    Department of Immunodermatology, Istituto Dermopatico dell Immacolata, IDI, IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy
    Eur J Dermatol 12:27-31. 2002
    ....
  5. doi request reprint Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools
    Andrea Paradisi
    Health Services Research Unit, Istituto Dermopatico dell Immacolata Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
    J Am Acad Dermatol 60:261-9. 2009
    ..Very few studies have investigated the quality of life (QoL) of patients with pemphigus, all reporting a strong impact on physical and emotional status...
  6. pmc Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface
    Giovanni Di Zenzo
    Molecular and Cell Biology Laboratory, Istituto Dermopatico dell Immacolata, IDI IRCCS, Rome, Italy
    J Clin Invest 122:3781-90. 2012
    ....
  7. ncbi request reprint Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial
    Leon F Mentink
    Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Arch Dermatol 142:570-6. 2006
    ..To determine the therapeutic effect of adjuvant dexamethasone pulse therapy when given in addition to conventional treatment of pemphigus vulgaris...
  8. pmc Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
    Dedee F Murrell
    Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
    J Am Acad Dermatol 58:1043-6. 2008
    ..These should assist in development of consistent reporting of outcomes in future studies...